Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Bristol-Myers Squibb Builds Biologics Plant

by Ann M. Thayer
November 24, 2014 | A version of this story appeared in Volume 92, Issue 47
Advertisement

Most Popular in Pharmaceuticals

[+]Enlarge
Credit: Bristol-Myers Squibb
BMS also invested about $900 million in this biologics plant in Devens, Mass.
A steel reaction vessel festooned with ports, gauges, and wires. Several similar tanks can be seen in the background.
Credit: Bristol-Myers Squibb
BMS also invested about $900 million in this biologics plant in Devens, Mass.

Bristol-Myers Squibb expects to spend about $900 million to construct a biologics manufacturing facility in Cruiserath, County Dublin, Ireland. The firm already has a small-molecule drug plant at the site. The 30,000 m2 facility will house six 15,000-L bioreactors, along with areas for purification, offices, and labs. When operational in 2019, the plant will employ 350 to 400 scientists, engineers, bioprocess operators, quality specialists, and other skilled professionals, BMS says.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society

You might also like...

SK invests at Ireland pharmaceutical chemical facility
Piramal invests in UK drug chemical facilities
Serving the chemical, life science, and laboratory worlds
Flamma starts digging on R&D expansion

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE